Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC2-25 cream in CKD-associated pruritus
NCT05482698Phase 2Completed
- Sponsor
- MC2 Therapeutics
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alanyl glutamine in chronic kidney disease (CKD), sponsored by MC2 Therapeutics. Started Jul 2022; status: completed.
02
Drugs
alanyl glutamine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05482698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482698.